Literature DB >> 2850984

Primary hepatic cancer--the role of limited resection and total hepatectomy with orthotopic liver replacement.

J M Funovics1, A Fritsch, F Herbst, F Piza, F Mühlbacher, F Längle, M Schemper.   

Abstract

Between 1977 and 1986, 172 patients with primary hepatic cancer were treated at the Department of Surgery I, University of Vienna Medical School. In 76 cases (80%) males, 20% females), cirrhosis of the liver was also present. Ninety patients underwent curative surgery (hepatic resection in 64, and liver transplantation in 26 cases). There were no early tumor stages. Forty-five large tumors were confined to one lobe, 42 involved both lobes, 3 even invaded adjacent structures, the majority (74%) being hepatocellular carcinomas. Forty-four of the 64 liver resections were performed in patients with otherwise normal livers (mortality 18%), while 20 patients had associated liver cirrhosis. In view of the extremely high mortality rates after extended liver resection, only limited local resections have been performed in cirrhotic malignancies since 1982 (mortality 25%). Perioperative mortality (25% overall) was due mainly to hepatic failure and sepsis; non-fatal complications occurred in 12 patients (26%). Seventeen of the 26 liver transplants were cirrhotic hepatomas. Nine deaths (34%) were caused by technical problems (graft failure, clotting disorder after massive transfusion) and systemic infections. The outcome for the patient after the immediate postoperative period was determined by tumor regrowth (residual liver tissue, graft, distant metastases) in both groups (median life expectancy 18.4 months after radical liver resection and 18.6 months after liver transplantation). Surgery is the only alternative for these patients (50% survival of untreated hepatoma: 2.6 months), improving both their quality of life and survival. We believe that in carefully selected candidates with non-resectable tumors liver replacement may be a useful alternative.

Entities:  

Mesh:

Year:  1988        PMID: 2850984

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

Review 1.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

Review 2.  Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors:  Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-17       Impact factor: 46.802

Review 3.  Practical considerations in the treatment of hepatocellular carcinoma.

Authors:  M Colleoni; R A Audisio; F De Braud; N Fazio; G Martinelli; A Goldhirsch
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 4.  Liver transplantation for hepatocellular carcinoma: clinical results and future aspects.

Authors:  R Pichlmayr; A Weimann; G Steinhoff; B Ringe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Hepatic resection versus transplantation for hepatocellular carcinoma.

Authors:  S Iwatsuki; T E Starzl; D G Sheahan; I Yokoyama; A J Demetris; S Todo; A G Tzakis; D H Van Thiel; B Carr; R Selby
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

Review 6.  [Liver resections for primary liver malignancies. Personal results and analysis of the literature].

Authors:  J Zieren; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir       Date:  1994

7.  Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

Authors:  B Ringe; R Pichlmayr; C Wittekind; G Tusch
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

8.  Role of liver transplantation in the treatment of unresectable liver cancer.

Authors:  R Pichlmayr; A Weimann; K J Oldhafer; H J Schlitt; J Klempnauer; A Bornscheuer; A Chavan; E Schmoll; H Lang; G Tusch
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.